acid sphingomyelinase
Acid sphingomyelinase is one of the enzymes that make up the sphingomyelinase (SMase) family, responsible for catalyzing the breakdown of sphingomyelin to ceramide and phosphorylcholine. They are organized into alkaline, neutral, and acidic SMase depending on the pH in which their enzymatic activity is optimal. Acid sphingomyelinases' (aSMases) enzymatic activity can be influenced by drugs, lipids, cations, pH, redox and other proteins in the environment. Specifically aSMases have been shown to have increased enzymatic activity in lysobisphosphatidic acid (LBPA) or phosphatidylinositol (PI) enriched environments, and inhibited activity when phosphorylated derivatives of PI are present. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Dec 1, 2006 (NCT00410566)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Sphingomyelin phosphodiesteraseSupplementation
SMPD1 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAcid sphingomyelinase ↗
Also known as
- acid sphingomyelinase
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01722526 | Phase 1 | Mar 1, 2013 | Genzyme |
| NCT00410566 | Phase 1 | Dec 1, 2006 | Genzyme |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genzyme | For profit | 2 | 2 | 1 | 2006 |